Back to Journals » Cancer Management and Research » Volume 11

KIF15 promotes bladder cancer proliferation via the MEK–ERK signaling pathway

Authors Zhao H, Bo Q, Wu Z, Liu Q, Li Y, Zhang N, Guo H, Shi B

Received 22 October 2018

Accepted for publication 7 January 2019

Published 26 February 2019 Volume 2019:11 Pages 1857—1868

DOI https://doi.org/10.2147/CMAR.S191681

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Ahmet Emre Eskazan


Hongda Zhao,* Qiyu Bo,* Zonglong Wu, Qinggang Liu, Yan Li, Ning Zhang, Hu Guo, Benkang Shi

Department of Urology, Qilu Hospital of Shandong University, Jinan, China

*These authors contributed equally to this work

Background: Bladder cancer (BC) is the most common cancer of the urinary tract and invariably predicts a poor prognosis. In this study, we found a reliable gene signature and potential biomarker for predicting clinical prognosis.
Methods: The gene expression profiles were obtained from the GEO database. By performing GEO2R analysis, numerous differentially expressed genes (DEGs) were found. Three different microarray datasets were integrated in order to more precisely identify up-expression genes. Functional analysis revealed that these genes were mainly involved in cell cycle, DNA replication and metabolic pathways.
Results: Based on protein-protein interactome (PPI) networks that were identified in the current study and previous studies, we focused on KIF15 for further study. The results showed that KIF15 promotes BC cell proliferation via the MEK -ERK pathway, and Kaplan‐Meier survival analysis revealed that KIF15 expression was an independent prognostic risk factor in BC patients.
Conclusion: KIF15 may represent a promising prognostic biomarker and a potential therapeutic option for BC.

Keywords: KIF15, bladder cancer, proliferation, MEK–ERK

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]